Corxel

formerly Jixing Pharmaceuticals

Developing innovative cardiometabolic therapies globally

Corxel was founded in 2019, is headquartered in United States, lists 51–200 employees, and has $581.5M in recorded funding across 4 rounds.

Headquarters
New Jersey
Employees
51–200
Founded
2019
Business Model
B2B
Total Funding
$581.5M
Last Round
$287.0M Series DJan 2026
Rounds
4

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 4 funding rounds and 9 investors for this company. The full record is or through the API.

About

CORXEL (formerly Ji Xing Pharmaceuticals, founded 2019) is a clinical-stage biopharmaceutical company headquartered in the United States and China, focused on developing innovative therapies for patients with cardiometabolic conditions. The company's strategy centers on identifying and in-licensing clinical-stage assets against validated cardiometabolic targets — including obesity, type 2 diabetes, hypertension, and acute cardiovascular events — and advancing them through mid- and late-stage development across global and regional pathways. Its lead program, CX11, is an oral small-molecule GLP-1 receptor agonist in Phase II development for obesity and type 2 diabetes. In January 2026, CORXEL completed a $287 million Series D1 financing to advance its cardiometabolic pipeline.

Summary

Corxel is a Biotech company based in United States, founded in 2019. It lists 51–200 employees. It has raised $581.5M in total across 4 rounds, most recently a $287.0M Series D round in Jan 2026. Investors include RTW Investments, SR One and Leaps by Bayer.

Funding History

Series DSeries DJan 2026
$287.0M

Sign up to see all 4 events

Funding: Series D. Amounts, valuations, and investors where available.

Investors

Similar Companies

Tiantan Biological / China Biologic (泰邦生物集团)

China's leading blood products manufacturer

Beijing, China1001–5000Biotech, Healthcare
Growth EquityTotal funding$5.1BAug 2022
Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019
Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech, Healthcare
Private EquityTotal funding$3.0BJan 2004
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
Syneos HealthAcquired

Integrated biopharmaceutical solutions company

Burlington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.0BMay 2017
BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech, Oncology
Corporate RoundTotal funding$2.8BJan 2020

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Corxel on Indexed.vc
<a href="https://indexed.vc/companies/corxel"><img src="https://indexed.vc/api/badge/company/corxel" alt="Corxel on Indexed.vc" width="260" height="76" /></a>